Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00467428|
Recruitment Status : Completed
First Posted : April 30, 2007
Last Update Posted : April 30, 2007
|Condition or disease||Intervention/treatment||Phase|
|Attention Deficit Hyperactivity Disorder||Drug: NS2359 Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||126 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder. A Randomised, Double-Blind, Placebo-Controlled Study|
|Study Start Date :||August 2003|
|Actual Study Completion Date :||September 2004|
- To investigate the efficacy of NS2359 in adult patients diagnosed with ADHD (predominantly inattentive, predominantly hyperactive/impulsive or combined) according to DSM-IV criteria.
- To investigate the safety and tolerability of NS2359 in adult ADHD patients.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00467428
|United States, Massachusetts|
|Adult and Pediatric Psychopharmacology, Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||Thimothy Wilens, MD||Adult and Pediatric Psychopharmacology, Masschusetts General Hospial, Boston, US|